NDAORALFOR SUSPENSION
Approved
Aug 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
KONVOMEP (omeprazole and sodium bicarbonate) by R-Pharm US is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the h+/k+ atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for active benign gastric ulcer ( ), risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KONVOMEP is an oral suspension combining omeprazole and sodium bicarbonate, a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+ ATPase enzyme system in gastric parietal cells. It is indicated for active benign gastric ulcer and risk reduction of upper GI bleeding in critically ill patients. The sodium bicarbonate component enables rapid acid neutralization, allowing faster omeprazole activation.
$0.002BPart D
Peak13.8 years to LOEEarly-stage revenue growth with modest Part D penetration suggests a niche product with limited team expansion opportunity despite peak lifecycle status.
Mechanism of Action
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has…
Worked on KONVOMEP at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.